Join 7,195 other subscribers
Tag Archives: GSK
Guest Blogspot: The Pharmaceutical Industry – Friend or Foe?
Recent months have seen publicity over examples of disgraceful behaviour by pharmaceutical companies. The question arises as to whether the failings have been rare and exceptional or whether they are indicative of generally low moral standards in the industry. Pharmaceutical … Continue reading
Posted in Alcohol, Business, Drugs, Finance, GPs, Information, NHS, Obesity, Research Tagged 2020health, Abbott, alcohol, AstraZeneca, bribes, criminal, dishonest, Drugs, General practitioner, government, GP, GPs, GSK, innovation, Kuno Sommer, law breaking, life expectancy, Lilly, medicine, misleading, National Health Service, NHS, Obesity, patient, Patients, Paxil, Pfizer, pharmaceutical, practolol, pricing, R&D, Research, Responsibility in healthcare, Seroquel, thalidomide, tobacco, Wellbutrin, wrongdoing, Zhen Xiaoyu Leave a comment
Guest Blogspot: A wrong decision on UK drug pricing could seriously undermine all the good work that HM Treasury and the Department for Business, Innovation and Skills have done to encourage the UK pharmaceutical industry.
The recent local elections highlight the political dangers ahead. The current UK coalition government has lost popularity through decisions that do not all relate to austerity measures. Shortly after the General Election Andrew Lansley’s plans to increase the say of … Continue reading
Posted in Andrew Lansley, Business, Department of Health, Drugs, Election, Global Health, Health Bill, NHS, Patient choice, Patients, Pharma, Policy, Research, Technology Tagged 2020health, Andrew Lansley, AstraZeneca, Department of Health, Drugs, GlaxoSmithKline, GSK, health, Health Bill, innovation, medicine, National Health Service, NHS, NICE, patient, Patients, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing Leave a comment